Patents by Inventor Kelvin K. C. Sham
Kelvin K. C. Sham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8952037Abstract: Heteroaryloxycarbocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.Type: GrantFiled: May 11, 2011Date of Patent: February 10, 2015Assignee: Amgen Inc.Inventors: Jennifer R. Allen, Michael J. Frohn, Paul E. Harrington, Essa Hu, Alexander J. Pickrell, Robert M. Rzasa, Kelvin K. C. Sham
-
Patent number: 8314131Abstract: The present invention comprises a new class of compounds useful for modulating the activity of p38 MAP kinase. The compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R1 and R5 are defined herein. The invention further provides pharmaceutical compositions including one or more compounds of Formula I, use of such compounds and compositions for treatment of p38 MAP kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: September 19, 2008Date of Patent: November 20, 2012Assignee: Amgen Inc.Inventors: Liping H. Pettus, Kelvin K. C. Sham, Andrew Tasker, Shimin Xu
-
Patent number: 8101612Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of p38 kinase mediated diseases and related inflammatory conditions. The compounds have a general Formula II wherein L1, L2, R1a, R1b, R1c, R2, R3, R3a, R4, R5 and p are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: September 4, 2007Date of Patent: January 24, 2012Assignee: Amgen Inc.Inventors: Andrew Tasker, Dawei Zhang, Liping H. Pettus, Rob M. Rzasa, Kelvin K. C. Sham, Shimin Xu, Partha Chakrabarti
-
Publication number: 20110306591Abstract: Heteroaryloxycarbocyclyl compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.Type: ApplicationFiled: May 11, 2011Publication date: December 15, 2011Inventors: Jennifer R. Allen, Michael J. Frohn, Paul E. Harrington, Essa Hu, Alexander J. Pickrell, Robert M. Rzasa, Kelvin K. C. Sham
-
Patent number: 7935709Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of pro-inflammatory cytokine mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein s, T, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use such as treatment of p38 mediated diseases by administering the compounds of Formula I or compositions including the compounds of Formula I, and intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: July 16, 2007Date of Patent: May 3, 2011Assignee: Amgen Inc.Inventors: Fang-Tsao Hong, Kelvin K. C. Sham, Seifu Tadesse, Andrew Tasker
-
Patent number: 7842685Abstract: The present invention relates to compounds of Formula (I): that are have activity as S1P receptor modulating agents, more specifically to specifically compounds that are S1P1 receptor agonists. The invention also related to the use of such compounds to treat diseases associated with inappropriate S1P1 receptor activity such as autoimmune diseases.Type: GrantFiled: June 18, 2009Date of Patent: November 30, 2010Assignee: Amgen Inc.Inventors: Victor J. Cee, Michael J. Frohn, Brian Alan Lanman, Susana C. Neira, Anthony B. Reed, Kelvin K. C. Sham
-
Publication number: 20100292234Abstract: The present invention comprises a new class of compounds useful for modulating the activity of p38 MAP kinase. The compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R1 and R5 are defined herein. The invention further provides pharmaceutical compositions including one or more compounds of Formula I, use of such compounds and compositions for treatment of p38 MAP kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammatory disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: ApplicationFiled: September 19, 2008Publication date: November 18, 2010Applicant: Amgen Inc.Inventors: Liping H. Pettus, Kelvin K.C. Sham, Andrew Tasker, Shimin Xu
-
Patent number: 7759337Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein B, R1, R2, R3, R4 and R5 are d.efined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: March 2, 2006Date of Patent: July 20, 2010Assignee: Amgen Inc.Inventors: Andrew Tasker, Dawei Zhang, Guo-Qiang Cao, Partha Pratim Chakrabarti, James Richard Falsey, Bradley J. Herberich, Randall W. Hungate, Liping H. Pettus, Anthony Reed, Robert M. Rzasa, Kelvin K. C. Sham, Maya C. Thaman, Shimin Xu
-
Patent number: 7700593Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: GrantFiled: October 5, 2007Date of Patent: April 20, 2010Assignee: Amgen Inc.Inventors: Dawei Zhang, Andrew Tasker, Kelvin K. C. Sham, Partha Pratim Chakrabarti, James Richard Falsey, Bradley J. Herberich, Liping H. Pettus, Robert M. Rzasa
-
Publication number: 20100029611Abstract: The present invention relates to compounds of Formula (I): that are have activity as S1P receptor modulating agents, more specifically to specifically compounds that are S1P1 receptor agonists. The invention also related to the use of such compounds to treat diseases associated with inappropriate S1P1 receptor activity such as autoimmune diseases.Type: ApplicationFiled: June 18, 2009Publication date: February 4, 2010Applicant: Amgen Inc.Inventors: Victor J. Cee, Michael J. Frohn, Brian Alan Lanman, Susana C. Neira, Anthony B. Reed, Kelvin K.C. Sham
-
Patent number: 7582631Abstract: The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs.Type: GrantFiled: January 11, 2005Date of Patent: September 1, 2009Assignee: Amgen Inc.Inventors: Celia Dominguez, Anthony Reed, Kelvin K. C. Sham, Maya C. Thaman
-
Publication number: 20090149468Abstract: The present invention relates to therapeutic diazobicyclo pyridines and their use in the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis or osteoarthritis, organ transplant, acute transplant or heterograft and homograft rejection, ischemic and reperfusion injury, transplantation tolerance induction, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lupus, graft vs.Type: ApplicationFiled: February 4, 2009Publication date: June 11, 2009Applicant: Amgen Inc.Inventors: Guo-Qiang Cao, Jian J. Chen, Celia Dominguez, Anthony Reed, Kelvin K.C. Sham, Maya C. Thaman, Dawei Zhang, Bradley J. Herberich
-
Publication number: 20080161303Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of P38 map kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: ApplicationFiled: October 5, 2007Publication date: July 3, 2008Applicant: Amgen Inc.Inventors: Dawei Zhang, Andrew Tasker, Kelvin K.C. Sham, Partha Pratim Chakrabarti, James Richard Falsey, Bradley J. Herberich, Liping H. Pettus, Robert M. Rzasa
-
Publication number: 20080119468Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.Type: ApplicationFiled: September 4, 2007Publication date: May 22, 2008Applicant: Amgen Inc.Inventors: Andrew Tasker, Dawei Zhang, Liping H. Pettus, Rob M. Rzasa, Kelvin K.C. Sham, Shimin Xu, Partha Chakrabarti
-
Patent number: 7026326Abstract: The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6alkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs.Type: GrantFiled: May 13, 2003Date of Patent: April 11, 2006Assignee: Amgen Inc.Inventors: Guo-Qiang Cao, Celia Dominguez, Martin H. Goldberg, Fang-Tsao Hong, Kelvin K. C. Sham, Seifu Tadesse, Nuria A. Tamayo, Kurt E. Weiler, Dawei Zhang, Hongyu Liao
-
Patent number: 6967254Abstract: The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs.Type: GrantFiled: September 8, 2003Date of Patent: November 22, 2005Assignee: Amgen Inc.Inventors: Celia Dominguez, Dawei Zhang, Kelvin K. C. Sham, Guo-Qiang Cao